Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Read more about Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review.
Radiotherapy-induced severe oral mucositis: pharmacotherapies in recent and current clinical trials. Read more about Radiotherapy-induced severe oral mucositis: pharmacotherapies in recent and current clinical trials.
Key challenges for drugs in clinical development for cholangiocarcinoma. Read more about Key challenges for drugs in clinical development for cholangiocarcinoma.
Investigational multitargeted kinase inhibitors in development for head and neck neoplasms. Read more about Investigational multitargeted kinase inhibitors in development for head and neck neoplasms.
Phase II investigational oral drugs for the treatment of radio/chemotherapy induced oral mucositis. Read more about Phase II investigational oral drugs for the treatment of radio/chemotherapy induced oral mucositis.
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Read more about RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.
Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. Read more about Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma.
Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Read more about Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma.
Arzoxifene: the development and clinical outcome of an ideal SERM. Read more about Arzoxifene: the development and clinical outcome of an ideal SERM.
